Related Experiment Video
Updated: Aug 12, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Postnatal corticosteroids and developmental outcomes in extremely preterm or extremely low birth weight infants: The
Ellen Douglas1, Kate A Hodgson1,2, Joy E Olsen1,3
1Newborn Research Centre, Royal Women's Hospital, Melbourne, Victoria, Australia.
Insights
High cumulative postnatal corticosteroid doses in extremely preterm (EP) or extremely low birth weight (ELBW) infants are linked to increased cerebral palsy risk. Further research is needed to confirm effects on neurodevelopmental outcomes.
Area of Science:
- Neonatal Medicine
- Developmental Pediatrics
- Pharmacology
Background:
- Systemic postnatal corticosteroids are used for bronchopulmonary dysplasia (BPD) in extremely preterm (EP) or extremely low birth weight (ELBW) infants.
- These treatments carry risks of long-term harm.
Purpose of the Study:
- To investigate the association between cumulative postnatal corticosteroid dose and neurodevelopmental outcomes in EP/ELBW infants.
Main Methods:
- A longitudinal cohort study of EP/ELBW livebirths in Victoria, Australia (2016-2017).
- Neurodevelopmental assessment at 2 years corrected age.
- Linear and logistic regression analyses adjusted for gestational age, birth weight, sex, and intraventricular hemorrhage.
Main Results:
- Higher cumulative corticosteroid doses were associated with increased odds of cerebral palsy (adjusted OR 1.47).
- A trend towards lower cognitive and motor scores was observed, but this weakened after adjustment for confounders.
Conclusions:
- Increased cumulative postnatal corticosteroid dose in EP/ELBW infants correlates with higher cerebral palsy rates at 2 years corrected age.
- Larger studies are required to fully elucidate the independent impact of cumulative steroid dose on neurodevelopment.
Aim:
Systemic postnatal corticosteroids are used to treat or prevent bronchopulmonary dysplasia (BPD) in extremely preterm (EP) or extremely low birth weight (ELBW) infants but are associated with long-term harm. We aimed to assess the relationship between cumulative postnatal corticosteroid dose and neurodevelopmental outcomes.
Methods:
Longitudinal cohort study of all EP/ELBW livebirths in Victoria, Australia 2016-2017. Perinatal data were collected prospectively. Neurodevelopmental assessment was performed at 2 years' corrected age. Linear and logistic regression were used to determine relationships between cumulative corticosteroid dose and neurodevelopment, adjusted for gestational age, birth weight, sex and major intraventricular haemorrhage.
Results:
Seventy-six EP/ELBW infants received postnatal corticosteroids to treat or prevent BPD, 62/65 survivors were seen at 2 years. Median (IQR) cumulative postnatal corticosteroid dose was 1.36 (0.92-3.45) mg/kg dexamethasone equivalent. Higher cumulative corticosteroid dose was associated with increased odds of cerebral palsy, adjusted OR (95% CI) 1.47 (1.04, 2.07). Higher cumulative corticosteroid dose was also associated with lower cognitive and motor developmental scores, however, this weakened after adjustment for confounding variables: cognitive composite score adjusted coefficient (95% CI) -1.3 (-2.7, 0.1) and motor composite score adjusted coefficient (95% CI) -1.3 (-2.8, 0.2).
Conclusion:
Higher cumulative postnatal corticosteroid dose in EP/ELBW infants is associated with increased odds of cerebral palsy at 2 years' corrected age. Adequately powered studies are needed to assess the independent effects of cumulative steroid dose on neurodevelopmental outcomes.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Teratogenicity
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Regression Toward the Mean

